sb-277,011-a sb-277,011-a sb-277,011a is a drug which acts as a potent and selective dopamine d3 receptor antagonist, which is around 80-100x selective for d3 over d2, and lacks any partial agonist activity. sb-277,011-aidentifiers iupac name n-quinoline-4-carboxamide pubchem cid5311096iuphar/bps143chemspider4470626 nchemblchembl85606 ncomptox dashboard (epa)dtxsid10944188 chemical and physical dataformulac28h30n4omolar mass438.575 g·mol−13d model (jsmol)interactive image smiles c4cccc1c4nccc1c(=o)nc3ccc(cc3)ccn(ccc2c5)cc2ccc5c#n inchi inchi=1s/c28h30n4o/c29-18-21-5-8-23-19-32(16-13-22(23)17-21)15-12-20-6-9-24(10-7-20)31-28(33)26-11-14-30-27-4-2-1-3-25(26)27/h1-5,8,11,14,17,20,24h,6-7,9-10,12-13,15-16,19h2,(h,31,33) nkey:olwrvvhpjflnpw-uhfffaoysa-n n ny (what is this?) (verify) sb-277,011a is used in the study of addiction to stimulant drugs such as nicotine and cocaine. where cocaine reduces the threshold for brain electrical self-stimulation in rats, an indication of cocaine's rewarding effects, sb-277,011a completely reverses this effect. it may thus be useful in the treatment of addiction to nicotine and cocaine, and is also being investigated for potential uses in the treatment of other drug addictions, such as addiction to heroin and alcohol. another potential application for sb-277,011a is in the treatment of schizophrenia, and it may be particularly useful in treating comorbid patients who are both schizophrenic and addicted to drugs. however it may worsen side effects such as tardive dyskinesia in patients who are already prescribed antipsychotic drugs.